Filling Systems in Advanced Therapy Laboratories: Automation and Process Optimization

Advanced therapy laboratories are reshaping the future of medicine, developing innovative solutions based on gene therapy, cell therapy, and tissue engineering. These new treatments, known as Advanced Therapy Medicinal Products (ATMPs), offer hope for diseases that currently lack effective therapeutic options. However, their production requires highly specialized processes, with aseptic filling systems playing a critical role. These technologies ensure sterility, safety, and product quality, guaranteeing that patients receive treatments in the best possible conditions.

In this article, we will explore how these systems work, the benefits of their automation, and the regulatory framework governing biotechnology laboratories.

How Do Filling Systems Work in Advanced Therapy Laboratories?

Filling systems are essential in the production of advanced therapies, ensuring that ATMPs are packaged safely and accurately. These systems operate under controlled conditions to prevent contamination and ensure that each dose meets the required quality standards.

There are two main types of filling systems: manual and automated. Manual systems are ideal for small batches and are typically used under laminar flow hoods. Automated systems, on the other hand, offer greater precision, scalability, and efficiency, making them the preferred option for large-scale production. Automation is particularly valuable in ATMP manufacturing, where sterility and consistency are critical.

To maintain aseptic conditions, these systems operate in Grade A cleanrooms, ensuring a sterile environment.

Benefits of Automation in Aseptic Filling Systems in the Pharmaceutical Industry

Aseptic filling is essential for drugs that cannot be sterilized after packaging, such as certain biologics or cell-based products. The automation of aseptic filling systems in the pharmaceutical industry has revolutionized this process: 

1. Enhanced Quality: Automated systems provide greater precision and consistency by reducing human error and ensuring that each dose meets strict quality standards.
2. Regulatory Compliance: These systems facilitate validation processes, demonstrating consistent performance and adherence to Good Manufacturing Practices (GMP) guidelines.
3. Controlled Environment: Automated systems maintain stable conditions of temperature, humidity, and pressure, reducing variability and ensuring product sterility.
4. Reduced Contamination Risk: By minimizing human intervention, these systems significantly lower the risk of exposure to contaminants.
5. Operational Efficiency: Automation optimizes production time and minimizes material waste, an essential factor in ATMP manufacturing, where raw materials are often scarce and costly.
6. Continuous Monitoring: Some systems incorporate real-time monitoring technologies, allowing dynamic adjustments to maintain product quality.

Regulatory Requirements for Filling Systems in Biotechnology Laboratories

Filling systems used in biotechnology laboratories must meet strict regulatory requirements to ensure product safety, quality, and efficacy.

Compliance with GMP Guidelines for Advanced Therapies

The Good Manufacturing Practice (GMP) guidelines specific to advanced therapy medicinal products are outlined in Volume 4 of the GMP framework. These guidelines set the minimum standards for all filling systems, ensuring that manufacturing processes are consistent, well-documented, and validated. Key GMP requirements include:

• Process Validation: Demonstrating that the aseptic filling system is reproducible and meets established standards. This includes Media Fill tests, which simulate aseptic filling to verify sterility while monitoring critical parameters such as pressure and airflow to ensure reproducibility.
• Quality Control: Implementing procedures to monitor and verify product quality at every production stage.
• Traceability: Maintaining detailed records of each production batch, including raw materials, manufacturing conditions, and test results.

Specific Regulations for Filling Systems in Advanced Therapies

Beyond GMP guidelines, filling systems in biotechnology laboratories must comply with additional regulations at European and national levels. Key regulations include:

• Regulation (EC) No 1394/2007: Establishes authorization, quality, and post-marketing surveillance requirements for advanced therapy medicinal products.
• Royal Decree-Law 477/2014: Governs the authorization of non-industrial manufacturing of advanced therapy medicinal products in Spain.

Aseptic filling systems are crucial in advanced therapies production, ensuring sterility, precision, and quality in every batch. Automation enhances efficiency and regulatory compliance, while adherence to European and national regulations is essential for ensuring product safety.

At Bexen Bioservices, we provide automated filling systems for advanced therapies, including our SIGNATA CT-5, a closed-system solution that eliminates the need for a laminar flow hood. This system combines efficiency, precision, and productivity while safeguarding product integrity throughout the process.

Contact us to learn more about how we can help you optimize your production process!

References

• Agencia Española de Medicamentos y Productos Sanitarios (Spain). Terapias avanzadas [Internet]. Madrid: Agencia Española de Medicamentos y Productos Sanitarios; [cited 07 March 2025]. Available from:https://www.aemps.gob.es/medicamentos-de-uso-humano/medicamentos-de-fabricacion-no-industrial/terapias-avanzadas/
• Agencia Estatal Boletín Oficial del Estado (Spain). Real Decreto 477/2014, de 13 de junio, por el que se regula la autorización de medicamentos de terapia avanzada de fabricación no industrial [Internet]. Madrid: Ministerio de Sanidad; [cited 07 March 2025]. Available from:https://www.boe.es/diario_boe/txt.php?id=BOE-A-2014-6277
• European Medicines Agency (The Netherlands). New guidelines on good manufacturing practices for advanced therapies [Internet]. Amsterdam: European Medicines Agency; 2017 November 24 [cited 07 March 2025]. Available from: https://health.ec.europa.eu/document/download/e1786e5d-1587-42af-b8ff-6a810ccb6836_en?filename=pharm731_2ib_atmps_guidelines.pdf
• European Union, Eur-Lex (Luxembourg). Reglamento (CE) n° 1394/2007 del Parlamento Europeo y del Consejo, de 13 de noviembre de 2007, sobre medicamentos de terapia avanzada y por el que se modifican la Directiva 2001/83/CE y el Reglamento (CE) n° 726/2004  [Internet]. Luxembourg: Publications Office of the European Union; 2007 November 13 [cited 07 March 2025]. Available from: https://eur-lex.europa.eu/legal-content/ES/ALL/?uri=celex:32007R1394
• Megías-Vericat JE, Bonora-Centelles A, Palanques-Pastor T, Aguilar CE, Guerreiro M, Gómez I, et al. Nuevos retos de las terapias avanzadas. Farmacia Hospitalaria. 2024;48:S21–S27. doi.org/10.1016/j.farma.2023.11.008.
• Ministerio de Sanidad (Spain). Parte IV. Directrices sobre normas de correcta fabricación específicas para Medicamentos de Terapia Avanzada [Internet]. Madrid: Ministerio de Sanidad; [cited 07 March 2025]. Available from:https://www.aemps.gob.es/industria/inspeccionNCF/guiaNCF/docs/normas-correcta-fabricacion/nueva-guia-NCF-ATMPs.pdf
• Ministerio de Sanidad y Política Social, Agencia Española de Medicamentos y Productos Sanitarios (Spain). NCF en medicamentos de terapia avanzada [Internet]. Madrid: Ministerio de Sanidad; [cited 07 March 2025]. Available from:https://www.aemps.gob.es/laAEMPS/eventos/medicamentos-uso-humano/2010/docs/terapias-Avanzadas_marzo-2010/ponencias/NCF_M.Moreno.pdf